Published in Blood on October 01, 1998
ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer (2010) 3.44
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A (2002) 2.74
High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest (2008) 1.61
Survival of the fittest: in vivo selection and stem cell gene therapy. Blood (2005) 1.19
A limited role for p16Ink4a and p19Arf in the loss of hematopoietic stem cells during proliferative stress. Blood (2005) 1.18
Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit. Endocr Rev (2010) 1.14
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood (2008) 1.04
Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A (2001) 0.92
Isolating gene-corrected stem cells without drug selection. Proc Natl Acad Sci U S A (2005) 0.90
Genome integrity, stem cells and hyaluronan. Aging (Albany NY) (2012) 0.87
Hematopoietic stem cell characterization and isolation. Methods Mol Biol (2011) 0.86
Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models. Semin Hematol (2013) 0.86
Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation. Immunol Res (2009) 0.82
Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci U S A (2002) 0.80
Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo. Proc Natl Acad Sci U S A (2002) 0.80
Gene therapy for Fabry disease. J Inherit Metab Dis (2001) 0.78
Multi-Drug Resistance ABC Transporter Inhibition Enhances Murine Ventral Prostate Stem/Progenitor Cell Differentiation. Stem Cells Dev (2015) 0.77
Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells. Gene Ther (2015) 0.77
Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1). J Exp Clin Cancer Res (2015) 0.77
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Tandem AP-1-binding sites within the human beta-globin dominant control region function as an inducible enhancer in erythroid cells. Genes Dev (1990) 4.07
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia (2005) 3.13
Inducibility of the HS II enhancer depends on binding of an erythroid specific nuclear protein. Nucleic Acids Res (1990) 2.01
Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci U S A (1995) 1.58
Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med (1998) 1.54
Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant (2001) 1.52
Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther (2003) 1.51
Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity (1999) 1.40
Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood (2000) 1.39
Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther (2001) 1.33
In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med (1998) 1.33
Mouse P-selectin glycoprotein ligand-1: molecular cloning, chromosomal localization, and expression of a functional P-selectin receptor. Blood (1996) 1.23
Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med (2013) 1.12
Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg (2000) 1.12
Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol (2001) 1.03
Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol (2007) 1.02
Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis (2001) 1.00
Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat Med (1998) 0.98
Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat Res (2000) 0.96
Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors. J Biol Chem (2000) 0.96
Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. J Biol Chem (2001) 0.96
Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. Ann N Y Acad Sci (1999) 0.94
Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene (2008) 0.93
GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. J Intern Med (2011) 0.92
Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum Gene Ther (2001) 0.92
Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43. J Biol Chem (2000) 0.91
A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther (2003) 0.91
Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant (2003) 0.89
Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem Pharmacol (2000) 0.87
Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis. Bone Marrow Transplant (2004) 0.87
Parathyroid hormone-related protein promotes quiescence and survival of serum-deprived chondrocytes by inhibiting rRNA synthesis. J Biol Chem (2001) 0.87
Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant (2004) 0.86
Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clin Cancer Res (1999) 0.86
High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells. Blood (2000) 0.85
Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant (2001) 0.85
Enuresis in sickle cell disease. J Urol (1995) 0.85
Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. Hum Gene Ther (2000) 0.85
Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense. Hum Gene Ther (2001) 0.85
A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood (1996) 0.84
Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood (1996) 0.84
Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood (1997) 0.84
Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet (1995) 0.82
Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant (2009) 0.82
Differences in body fat distribution and antioxidant status in Korean men with cardiovascular disease with or without diabetes. Am J Clin Nutr (2001) 0.82
In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application. Hum Mutat (1998) 0.82
Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Hum Gene Ther (1997) 0.82
Gene transfer into human hemopoietic progenitor cells. Br Med Bull (1995) 0.79
Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy (2002) 0.79
Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Hum Gene Ther (2000) 0.79
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant (2001) 0.79
Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX. Haemophilia (2007) 0.79
The carboxylation efficiency of the vitamin K-dependent clotting factors: studies with factor IX. Haemophilia (2008) 0.79
Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells (1998) 0.79
Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher (1999) 0.78
Ventricular activation of the atrial natriuretic factor gene in acute myocardial infarction. N Engl J Med (1988) 0.78
Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther (2002) 0.78
Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol (2001) 0.78
T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients. Immunol Res (2001) 0.78
The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood (2001) 0.78
Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant (2003) 0.78
Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia (1996) 0.77
A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease. Cell Transplant (2011) 0.77
Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin Cancer Res (1995) 0.77
Disruption of NF-kappa B signaling and chemokine gene activation by retroviral mediated expression of IKK gamma/NEMO mutants. Virology (2001) 0.77
Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci U S A (1999) 0.77
The effect of gnotobiotic rearing on porcine islet isolation and function. Transplant Proc (1996) 0.76
Spontaneous remission in monosomy 7 myelodysplastic syndrome. Br J Haematol (1995) 0.76
Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine (2011) 0.76
Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients. Bone Marrow Transplant (2001) 0.76
A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. Hum Gene Ther (1997) 0.76
Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells. Blood (2000) 0.75
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther (1994) 0.75
Minimization of the gliding index: criterion for the generation of the surfaces of a knee endoprosthesis. J Biomech (1987) 0.75
A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells. Hum Gene Ther (2001) 0.75
Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase. Cancer Gene Ther (1998) 0.75
Molecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis (2000) 0.75
The influence of collagenase solvent on the isolation of islets from 5 week old pigs: a comparison of TCM-199 and UW. J Mol Med (Berl) (1999) 0.75
Gene therapy in pediatric oncology. Invest New Drugs (1996) 0.75
Coding region-specific destabilization of mRNA transcripts attenuates expression from retroviral vectors containing class 1 aldehyde dehydrogenase cDNAs. Hum Gene Ther (1997) 0.75
Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies. Br J Haematol (1998) 0.75
Isolation, molecular cloning and in vitro expression of rhesus monkey (Macaca mulatta) prominin-1.s1 complementary DNA encoding a potential hematopoietic stem cell antigen. Tissue Antigens (2006) 0.75
Pseudotyped retrovectors for tumor-specific delivery of toxic suicide genes. IDrugs (2001) 0.75